Comments and Letters

  • Letter On Implementation of Meaningful Use 2 and re-implementation of Meaningful Use 3

    October 31, 2011
    October 31, 2011   Farzad Mostashari, MD, ScM Office of the National Coordinator for Health Information Technology U.S. Department of Health and Human Services 200 Independence Avenue S.W. Suite 729-D Washington, D.C. 20201   RE: Implementation of Meaningful Use 2 and re-implementation of Meaningful Use 3   Dear Dr. Mostashari,   The American Clinical Laboratory Association (ACLA) is an association representing clinical laboratories throughout theContinue Reading »...
  • Letter to Rep. Burgess Regarding the Modernizing Laboratory Test Standards for Patients Act

    October 14, 2011
        October 14, 2011   The Honorable Michael Burgess, MD United States House of Representatives 2241 Rayburn House Office Building Washington, D.C. 20515   Dear Congressman Burgess:   The American Clinical Laboratory Association (ACLA) is extremely pleased to offer our full and strong support for H.R. 3207 the Modernizing Laboratory Test Standards for Patients Act. This Bill is in lock‐step with the needContinue Reading »...
  • Comments to NIH Regarding Practical Utility of the Proposed Collection of Information for the Genetic Testing Registry

    September 26, 2011
        September 26, 2011  Genetic Testing Registry Staff National Institutes of Health Re:      Comments on the practical utility of the proposed collection of information for the Genetic Testing Registry The American Clinical Laboratory Association (ACLA) appreciates the opportunity to provide additional comments on the practical utility of the proposed collection of information for the Genetic Testing Registry (GTR). ACLA represents national, regional, andContinue Reading »...
  • Letter to HHS Regarding Nationwide Electronic Health Information Exchange

    September 23, 2011
      September 23, 2011 Department of Health & Human Services Office of the National Coordinator for Health Information Technology Attention: Stephen Posnack Hubert H. Humphrey Building 200 Independence Avenue, SW Suite 729D Washington, DC  20201 Re: Metadata Standards to Support Nationwide Electronic Health Information Exchange Dear Mr. Posnack: On behalf of the American Clinical Laboratory Association (“ACLA”), I am pleased to provide these comments onContinue Reading »...
  • AIM Letter to Sens Murray and Hensarling Regarding IOAS Letter

    September 20, 2011
        September 20, 2011   The Honorable Patty Murray, Co-Chair, Joint Select Committee on Deficit Reduction   The Honorable Jeb Hensarling, Co-Chair, Joint Select Committee on Deficit Reduction   Dear Chairwoman Murray and Chairman Hensarling:   On behalf of the Alliance for Integrity in Medicare (AIM), a coalition committed to ending the practice of inappropriate physician self-referral in Medicare, we recognize the challengesContinue Reading »...
  • Comments Regarding the 2012 PFS Proposed Rule

    August 30, 2011
    August 30, 2011 COMMENTS OF THE AMERICAN CLINICAL LABORATORY ASSOCIATION ON THE MEDICARE PROGRAM; PAYMENT POLICIES UNDER THE PHYSICIAN FEE SCHEDULE AND OTHER REVISIONS TO PART B FOR CY 2012 PROPOSED RULE (CMS-1524-P) The American Clinical Laboratory Association (ACLA) is pleased to have this opportunity to submit our comments on the Medicare Program; Payment Policies under the Physician Fee Schedule and Other Revisions to Part BContinue Reading »...
  • Letter to Joint Deficit Committee Members Regarding Coinsurance

    August 25, 2011
      August 25, 2011 The Honorable Fred Upton Chairman, House Energy and Commerce Committee 2183 Rayburn House Office Building United States House of Representatives Washington, DC 20515 Dear Representative Upton: I am writing you today on behalf of the American Clinical Laboratory Association (ACLA), which represents the leading national, regional, esoteric, pathology and ESRD clinical laboratories. As a member of the Joint Select CommitteeContinue Reading »...
  • Comments on RUO IUO

    August 24, 2011
      August 24, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville MD 20852 RE: Docket No, FDA-2011-D-0305 Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products labeled for Research Use Only or Investigational Use Only: Frequently Asked Ouestions Dear Sir or Madam: The American Clinical Laboratory Association (“ACLA”) is pleased to provide commentsContinue Reading »...
  • Comment to Centers for Medicare & Medicaid Services on New Genetic Codes

    July 18, 2011
      The American Clinical Laboratory Association (ACLA) is pleased to provide comments to the Centers for Medicare and Medicaid Services (CMS) on new genetic CPT codes being developed by the American Medical Association. ACLA is an association representing clinical and anatomic pathology laboratories throughout the country, including local, regional, and national laboratories. As providers of diagnostic testing services to Medicare beneficiaries, including genetic andContinue Reading »...
  • Letter to Senators Reid and McConnell, Representatives Boehner and Pelosi Regarding Coalition Letter Against Medicare Coinsurance for Lab Services

    July 11, 2011
      Dear Majority Leader Reid, Minority Leader McConnell, Speaker Boehner, and Minority Leader Pelosi: We, the undersigned organizations, represent the interests of a broad cross-section of our nation’s Medicare beneficiaries as well as the health care providers who care for them. While we believe it is critically important for our nation’s fiscal health to address the deficit, we are deeply concerned by a numberContinue Reading »...
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17